Skip to main content

Table 3 Distribution of stage of colorectal cancer by groups and other variables

From: Impact of the faecal immunochemical test on colorectal cancer survival

 

UNIVARIATE ANALYSIS

MULTIVARIATE ANALYSIS

EARLY STAGE (I, II) N = 711 N (%)

ADVANCED STAGE (III, IV) N = 814 N (%)

p

OR

95% CI

GROUP a

 Group 1

143 (51.3)

136 (48.7)

0.08

1

 

 Group 2

568 (45.5)

678 (54.5)

 

1.28

0.98–1.70

AGE (years)

  ≤ 49

33 (45.8)

39 (54.2)

 

1

 

 50–69

244 (49.9)

245 (50.1)

0.19

0.86

0.52–1.43

  ≥ 70

434 (45.0)

530 (55.0)

 

1.07

0.66–1.74

SITES

 Rectum

174 (47.4)

193 (52.6)

   

 Distal colon

310 (45.7)

368 (54.3)

0.71

 Proximal colon

220 (48.1)

237 (51.9)

   

 Unknown

7(30.4)

16(69.6)

   

HISTOLOGY

 Adenocarcinoma

683 (47.1)

766 (52.9)

 

1

0.64–2.04

 Mucinous adenocarcinoma

21 (43.7)

27 (56.3)

0.06

1.14

1.15–6.46

 Othersb

7 (25.0)

21 (75.0)

 

2.72

 
  1. OR odds ratio, CI confidence interval aGroup 1; with positive faecal immunochemical test results in the previous 12 months. Group 2: patients that either did not performed any FIT in the previous 12 months before diagnosis or display a negative FIT bOthers: signet ring cell carcinoma, neuroendocrine carcinoma, squamous cell carcinoma.